|Bid||82.68 x 800|
|Ask||82.71 x 1000|
|Day's Range||81.70 - 84.30|
|52 Week Range||73.12 - 88.32|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||39.71|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||1.12 (1.41%)|
|Ex-Dividend Date||Sep 02, 2021|
|1y Target Est||93.64|
DEERFIELD, Ill., October 28, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2021.
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
DEERFIELD, Ill. & MARCY L’ETOILE, France, October 21, 2021--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1